{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T23:44:20Z","timestamp":1768779860230,"version":"3.49.0"},"reference-count":28,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2006,3,27]],"date-time":"2006-03-27T00:00:00Z","timestamp":1143417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Gastrin hormone is trophic to in vitro gastric cancer, and the antigastrin antibodies (AGAs) are antiproliferative and antimetastatic. Human gastric cancers overexpress gastrin genes and receptors that react to gastrin's trophic effects. Immunogen G17DT elicits a specific and high\u2010affinity AGA. The authors evaluated G17DT vaccination given with cisplatin plus 5\u2010fluorouracil for the treatment gastric adenocarcinoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>In this multicenter, Phase II study, patients received G17DT vaccination intramuscularly on Weeks 1, 5, 9 and 25 and cisplatin plus 5\u2010fluorouracil every 28 days. Eligible patients had untreated, metastatic, or unresectable gastric or gastroesophageal adenocarcinoma with near\u2010normal organ function. The primary endpoint of the study was the over response rate (ORR), and secondary endpoints included overall survival (OS), safety, and the impact of successful vaccination on patient outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>In total, 103 patients were enrolled in 5 countries. Seven patients who were overdosed inadvertently with 5\u2010fluorouracil (a major protocol violation) were removed from the analysis. The confirmed ORR was 30% in 79 patients who were evaluated for response. The median time\u2010to\u2010progression (TTP) was 5.4 months, and the median survival (MS) was 9.0 months (<jats:italic>n<\/jats:italic> = 96 patients). Sixty\u2010five of 94 patients who were vaccinated (69%) had 2 consecutive AGA titers of \u22651 units (successfully vaccinated patients or immune\u2010responders). The TTP was longer in immune\u2010responders than in immune\u2010nonresponders (<jats:italic>P<\/jats:italic> = .0005). Similarly, the MS was longer in immune\u2010responders than in immune\u2010nonresponders (10.3 months vs. 3.8 months; <jats:italic>P<\/jats:italic> \u2264.0001). In a multivariate analysis, successful vaccination was an independent OS prognosticator (<jats:italic>P<\/jats:italic> = .0001). G17DT did not have an adverse effect on safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The results demonstrated that successful G17DT vaccination was correlated with longer TTP and MS. AGA response was an independent OS prognosticator. A Phase III evaluation of G17DT in gastric cancer is warranted. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21814","type":"journal-article","created":{"date-parts":[[2006,3,27]],"date-time":"2006-03-27T17:46:34Z","timestamp":1143481594000},"page":"1908-1916","source":"Crossref","is-referenced-by-count":66,"title":["An open\u2010label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5\u2010fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer : The GC4 study"],"prefix":"10.1002","volume":"106","author":[{"given":"Jaffer A.","family":"Ajani","sequence":"first","affiliation":[]},{"given":"J.","family":"Randolph Hecht","sequence":"additional","affiliation":[]},{"given":"Linus","family":"Ho","sequence":"additional","affiliation":[]},{"given":"Jackie","family":"Baker","sequence":"additional","affiliation":[]},{"given":"Marga","family":"Oortgiesen","sequence":"additional","affiliation":[]},{"given":"Arnavaz","family":"Eduljee","sequence":"additional","affiliation":[]},{"given":"Dov","family":"Michaeli","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2006,3,27]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"Aphton Investigator Brochure: Human G17DT Immunogen","author":"Aphton Corporation","year":"2003"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910300112"},{"key":"e_1_2_6_4_2","first-page":"1064","article-title":"Growth\u2010promoting effects of gastrin on human gastric carcinoma cell line TMK\u20101","volume":"76","author":"Ochai A","year":"1985","journal-title":"Jpn J Cancer Res."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1989.112"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(08)60403-0"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.42.6.795"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2004.01.004"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.7.2683.bloodjournal8872683"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.1.233"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0343"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:DDAS.0000037790.11724.70"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M002458200"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.2001.280.2.G298"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.6.813"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70412-4"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980316)75:6<873::AID-IJC9>3.0.CO;2-S"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910610216"},{"key":"e_1_2_6_19_2","first-page":"A37","article-title":"Gastrimmune reduces lung metastases in a human colorectal model","volume":"37","author":"Watson S","year":"1995","journal-title":"Gut."},{"key":"e_1_2_6_20_2","first-page":"880","article-title":"Gastrimmune raises antibodies that neutralize amidated and glycine\u2010extended gastrin\u201017 and inhibit the growth of colon cancer","volume":"56","author":"Watson SA","year":"1996","journal-title":"Cancer Res."},{"key":"e_1_2_6_21_2","first-page":"253","article-title":"Therapeutic effects of anti\u2010gastrin antibodies raised by gastrimmune on a human gastric cancer ascites line MGLVA1","volume":"436","author":"Watson SA","year":"1994","journal-title":"Proc AACR."},{"key":"e_1_2_6_22_2","first-page":"249","article-title":"Docetaxel (D), cisplatin, 5\u2010fluorouracil compare to cisplatin (C) and 5\u2010fluorouracil (F) for chemotherapy\u2010naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomized Phase III trial (V325)","volume":"22","author":"Ajani JA","year":"2003","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.14.2648"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)90170-8"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930615)71:12<3813::AID-CNCR2820711205>3.0.CO;2-5"},{"issue":"6","key":"e_1_2_6_26_2","first-page":"1983","article-title":"A randomized, comparative study of combination chemotherapies in advanced gastric cancer: 5\u2010fluorouracil and cisplatin (FP) versus 5\u2010fluorouracil, cisplatin, and 4\u2032\u2010epirubicin (FPEPIR)","volume":"12","author":"Kyoto Research Group for Chemotherapy of Gastric Cancer (KRGCGC)","year":"1992","journal-title":"Anticancer Res."},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a057858"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.130"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199512000-00005"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21814","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:27:05Z","timestamp":1760268425000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,27]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["10.1002\/cncr.21814"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21814","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,27]]}}}